Company Overview and News

Stop missing out on important events!

Fintel provides real time notifications of important company events such as major investments (13D/G filings), insider trades (SEC form 4), and important SEC filings. Sign up and create your company alerts for free.

Headline News

Helix Biopharma Corp. and Helix Immuno-Oncology to Present at the AACR Annual Meeting 2018 in Chicago

2018-02-06 marketwired
RICHMOND HILL, ONTARIO--(Marketwired - Feb. 6, 2018) - Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that together with its wholly-owned subsidiary Helix Immuno-Oncology, it will present a poster entitled: Targeting Urease to Human VEGFR2 Elicits Antitumor Activity in Triple-Negative Breast Cancer Models at the American Association for Cancer Research ("AACR") Annual Meeting 2018 which is taking place on April 14 - 18, 2018 at McCormick Place in Chicago, Illinois. (1-0)

Helix Biopharma Corp. to Present at the Biotech Showcase Conference

2018-01-05 marketwired
RICHMOND HILL, ONTARIO--(Marketwired - Jan. 5, 2018) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has been selected to present at the Biotech Showcase Conference on Monday, January 8, 2018 at 4:30pm (PT) at Hilton San Francisco Union Square. (1-0)

Helix Biopharma Corp. Signs Binding Letter of Intent for Development of New CAR-T Technologies

2018-01-04 marketwired
RICHMOND HILL, ONTARIO--(Marketwired - Jan. 4, 2018) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the finalization of a collaborative binding letter of intent ("LOI") with ProMab Biotechnologies, Inc. ("ProMab") to develop chimeric antigen receptor T-cell therapy ("CAR-T") for hematological malignances and solid tumours. (1-0)

Helix BioPharma Corp. Closes Private Placement

2017-12-22 marketwired
RICHMOND HILL, ONTARIO--(Marketwired - Dec. 22, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD750,600. (1-0)

Helix BioPharma Corp. Announces Fiscal First Quarter 2018 Results

2017-12-14 marketwired
RICHMOND HILL, ONTARIO--(Marketwired - Dec. 13, 2017) - Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the first quarter of fiscal 2018 ending October 31, 2017. (1-0)

Helix BioPharma Corp. Announces Management Change

2017-12-01 marketwired
RICHMOND HILL, ONTARIO--(Marketwired - Dec. 1, 2017) - Helix BioPharma Corp. (TSX:HBP) (FRANKFURT:HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced Steve Demas, its Chief Operating Officer, has resigned due to personal reasons. "I want to thank Steve on behalf of Helix for his significant contribution to the Company," said Heman Chao, Chief Executive Officer. (1-0)

Helix BioPharma Corp. Announces Fiscal 2017 Year-End Results and Provides Research and Development Program Update

2017-10-28 marketwired
RICHMOND HILL, ONTARIO--(Marketwired - Oct. 27, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer, today announced its financial results for the year ended July 31, 2017 and an update on the Company's research and development programs. (16-1)

Helix BioPharma Corp. Closes Private Placement

2017-10-20 marketwired
RICHMOND HILL, ONTARIO--(Marketwired - Oct. 19, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of approximately CAD3,909,600. (1-0)

Helix BioPharma Corp. announces FDA approval to Accelerate Dose Escalation for U.S. Phase I Clinical Study

2017-09-27 marketwired
RICHMOND HILL, ONTARIO--(Marketwired - Sept. 27, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the U.S. Food and Drug Administration ("FDA") has approved an amendment to their U.S. Phase I study, protocol LDOS001, that will accelerate the dose escalation phase of the study. (1-0)

Helix Biopharma Corp. to Present at Third CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

2017-07-31 marketwired
TORONTO, ONTARIO--(Marketwired - July 31, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, is pleased to announce that the Company's poster entitled: "Immune checkpoint modulation by urease-mediated alkalization", has been accepted for presentation in the "Checkpoint Blockade Therapy" session at the Third International Cancer lmmunotherapy Conference.

Helix BioPharma Corp. Initiates Enrollment in the Third Dosing Cohort of U.S. Combination Treatment Study of Its Lung Cancer Drug Candidate L-DOS47

2017-07-25 marketwired
TORONTO, ONTARIO--(Marketwired - July 25, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the opening of patient screening in the third dosing cohort of its ongoing U.S. study of L-DOS47 in combination treatment with pemetrexed/carboplatin ("LDOS001").

Helix BioPharma Corp. and Moffitt Cancer Center to investigate L-DOS47 and checkpoint blockade

2017-07-19 marketwired
L-DOS47 therapy provides an alternative pharmacologic approach to neutralizing tumor acidity that may improve the response of immune checkpoint inhibitors

Helix BioPharma Corp. Director Resigns

2017-07-17 marketwired
TORONTO, ONTARIO--(Marketwired - July 17, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that the Board has accepted Mr. Albert Beraldo's resignation as director of the Company and Audit Committee Chair, effective July 14, 2017. Mr. Beraldo has conveyed to the Board that his other commitments have become too great for him to be able to fulfill the requirements of his position on the Board and determined it best for him to step down and make room for someone with the time and energy to devote to the Board and the Company.

Helix BioPharma Corp. Announces Collaboration with Moffitt Cancer Center

2017-07-11 marketwired
Helix to team up with Dr. Robert Gillies, Director of Moffitt's Cancer Imaging and Technology Center of Excellence on a research project aimed at extracting radiomics features from CT scans of late-stage lung cancer patients treated with L-DOS47

Helix BioPharma Corp. Announces Fiscal Third Quarter 2017 Results

2017-06-13 marketwired
TORONTO, ONTARIO--(Marketwired - June 13, 2017) - Helix BioPharma Corp. (TSX:HBP)(FRANKFURT:HBP) ("Helix" or the "Company"), a clinical stage immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces its financial results for its fiscal quarter ended April 30, 2017.